Proscia Presents Study Results On New Artificial Intelligence That Predicts Diagnostic Concordance For Melanoma
Source: Bio Space, November 2022
November 1, 2022 – PHILADELPHIA – Proscia®, a leading provider of digital and computational pathology solutions, has released study results on new artificial intelligence (AI) that predicts diagnostic agreement for melanoma, the deadliest form of skin cancer. The findings, which were presented at the European Conference on Computer Vision (ECCV) 2022, highlight the potential of the technology to improve diagnostic accuracy for melanoma and other diseases with low pathologist concordance.
Conducted at the University of Florida and Thomas Jefferson University, Proscia’s retrospective study “Using Whole Slide Image Representations from Self-Supervised Contrastive Learning for Melanoma Concordance Regression” demonstrated the AI’s performance on 1,412 whole slide images of skin biopsies. Each image was assessed by three to five dermatopathologists to establish a concordance rate. The R2 correlation between the technology’s predictions and the dermatopathologists’ concordance rates was 0.51.
In addition to this study, Proscia plans to conduct additional research illustrating the potential benefits of AI in helping pathologists to diagnose melanoma, including:
- Lowering the misdiagnosis rate for difficult cases. Melanoma often presents like benign mimickers, causing pathologists to disagree on its diagnosis 40% of the time.[2] As cases are often evaluated by only one pathologist, AI that predicts concordance with multiple experts could help to improve diagnostic accuracy by serving as a second set of eyes.
- Accelerating turnaround times for critical results. Over 15 million skin biopsies are taken annually in the United States[3], each of which may display one of hundreds of diagnoses. AI that predicts diagnostic agreement could flag cases that were likely to be challenging, driving efficiency gains by suggesting additional testing to provide a more complete look prior to pathologist review.
- Reducing costs and distress for patients. Frequent over-diagnosis of melanoma not only results in additional costs for health systems but also leads patients to pay for unnecessary treatment and cope with the stress of believing they have a life-threatening disease.[4] Increased diagnostic accuracy could help to eliminate these burdens.